This project, conducted in collaboration with Fiona Stanley Hospital, aims to develop an artificial intelligence (AI) system that can predict how relapsed lymphoma patients will respond to CAR-T cell therapy and anticipate potential side effects. Using past data, the study will analyze automated segmentations to identify important imaging features that can predict treatment outcomes, such as overall survival and progression-free survival, as well as expected toxicities like cytokine release syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome. Predicting which patients are likely to respond to therapy and which may experience significant side effects is crucial for tailoring personalized patient care.